Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Protalix BioTherapeutics, Inc.

Ticker
PLX
Sector
Healthcare
Industry
Biotechnology
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Protalix's regulatory progress, financial performance, and strategic partnerships.

Recent developments:
  • Protalix reported Q2 2026 earnings with positive net income and discussed business developments in an earnings call [N1].
  • FY25 results showed a net loss but included milestones related to Fabry disease treatment, indicating ongoing clinical and commercial activities [N2].
  • The European Commission approved dosing for Protalix's Fabry disease treatment, marking regulatory progress [N3].
  • HC Wainwright & Co. maintained a buy recommendation on Protalix in late 2025, reflecting analyst interest [N4].
  • Protalix's revenue increased by 16% in Q2 2025 compared to prior periods [N5].
  • Gilad Mamlok was named CFO in 2025, indicating management updates [N6].
  • The company presented at the H.C. Wainwright BioConnect Conference in 2025, engaging with investors and stakeholders [N7].
  • Quarterly earnings reports in 2025 showed narrowing losses and revenue growth [N8].
Overview

Protalix BioTherapeutics, Inc. is a biotechnology firm engaged in the development and commercialization of proprietary biologic drugs. The company operates primarily through a single segment and maintains partnerships with pharmaceutical companies such as Pfizer, Fiocruz, and Chiesi. Its revenue streams include product sales and licensing and research and development services. Financial disclosures indicate improving profitability and strong liquidity as of September 30, 2026. The company has been active in regulatory and clinical milestones, particularly related to treatments for Fabry disease.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Protalix BioTherapeutics, Inc. is a biotechnology company with a focus on proprietary biologic drugs. The company reported total revenue of $75.6 million and net income of $26.1 million for the nine months ended September 30, 2026. It maintains strong liquidity with a current ratio of 3.27 as of the same date. Recent developments include regulatory progress on its Fabry disease treatment and active partnerships with Pfizer, Fiocruz, and Chiesi. The company has shown revenue growth and management updates in recent periods [S1][S2][N1][N2][N3].

Scenarios for PLX

Bull case model:

The company has demonstrated revenue growth and returned to profitability in recent periods, supported by regulatory approvals such as the European Commission's approval of Fabry dosing. Strategic partnerships with Pfizer, Fiocruz, and Chiesi provide avenues for commercialization and development. Continued clinical progress and expanding product offerings could enhance its market presence.

Bear case model:

Risks include the inherent uncertainties in biotechnology development, including regulatory, clinical, and commercial execution risks. The company has experienced periods of net loss in prior years, indicating potential volatility in financial performance. Dependence on partnerships and licensing agreements may expose the company to external risks. Market competition and reimbursement challenges also pose risks to sustained growth.

Moat:

Protalix's moat is based on its proprietary biologic drug development platform and strategic partnerships with established pharmaceutical companies. Its regulatory approvals and ongoing clinical milestones, especially in rare diseases like Fabry disease, contribute to its competitive positioning. The company's ability to generate revenue from both product sales and licensing agreements supports its business model.

Risks overview
Risks summary
The biggest risks for Protalix relate to clinical and regulatory uncertainties inherent in biotech development, financial performance volatility, and dependence on external partnerships.
Risks details:

• Clinical and Regulatory Risks: The biotechnology industry involves significant clinical trial and regulatory approval risks that can impact product development timelines and commercialization.
• Financial Performance Volatility: Historical net losses and fluctuations in profitability indicate potential volatility in financial results.
• Dependence on Partnerships: Reliance on collaborations with companies like Pfizer and Chiesi exposes Protalix to risks related to partner decisions and performance.
• Market Competition and Reimbursement: Competition from other biotech firms and challenges in securing reimbursement for therapies may affect revenue growth.

FINAL FORECAST FOR PLX

Final take one line
Protalix BioTherapeutics exhibits strong business visibility with detailed financials, regulatory progress, and active partnerships.
Final take 12 to 24 month view

Business trends: Revenue growth and regulatory milestones in rare disease treatments, supported by strategic partnerships.
Execution milestones: Continued clinical development, regulatory approvals, and commercialization efforts for Fabry disease treatment.
Key risks: Clinical and regulatory uncertainties, financial performance volatility, and dependence on external partnerships.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Protalix BioTherapeutics, Inc. is a biotechnology company focused on developing and commercializing proprietary biologic drugs.
  • The company operates a single operating segment as per SEC filings [S1][S2].
  • Protalix's revenues come from selling goods and license and R&D services, with total revenue of $75.6 million for the nine months ended September 30, 2026, up from $43.6 million in the prior year period [S2].
  • The company reported net income of $26.1 million for the nine months ended September 30, 2026, compared to a net loss of $1.1 million in the prior year period [S2].
  • Basic earnings per share were $0.33 for the nine months ended September 30, 2026 [S2].
  • As of September 30, 2026, Protalix had cash and cash equivalents of $22.0 million and total current assets of $98.9 million, with current liabilities of $30.2 million, resulting in a current ratio of 3.27 and a cash ratio of 0.73 [S2].
  • The company had total assets of $118.2 million and total liabilities of $37.7 million as of September 30, 2026 [S2].
  • Protalix has agreements with partners including Pfizer, Fiocruz, and Chiesi for product development and commercialization [S1][S2].
  • Recent news highlights include the European Commission approving dosing for Protalix's Fabry disease treatment, indicating regulatory progress [N3].
  • The company reported Q2 2026 earnings with a positive net income and discussed business developments in an earnings call [N1].
  • FY25 results showed a net loss but also milestones related to Fabry disease treatment, reflecting ongoing clinical and commercial activities [N2].
  • Protalix has been active in investor relations and conferences, including presentations at H.C. Wainwright BioConnect Conference [N7].
  • The company named Gilad Mamlok as CFO in 2025, indicating management updates [N6].
  • Revenue growth was noted with a 16% increase in Q2 2025 compared to prior periods [N5].
  • HC Wainwright & Co. maintained a buy recommendation on Protalix in late 2025, reflecting analyst interest [N4].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-18 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-08-19 | www.nasdaq.com | Protalix (PLX) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/protalix-plx-q2-2026-earnings-call-transcript
  • N2 | 2026-03-19 | www.nasdaq.com | Protalix Stock Down As FY25 Results Show Net Loss, Fabry Milestones Boosts Outlook | https://www.nasdaq.com/articles/protalix-stock-down-fy25-results-show-net-loss-fabry-milestones-boosts-outlook
  • N3 | 2026-03-13 | www.nasdaq.com | European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication | https://www.nasdaq.com/articles/european-commission-approves-jj-prostate-drug-plx-fabry-dosing-incytes-zynyz-second
  • N4 | 2025-11-21 | www.nasdaq.com | HC Wainwright & Co. Maintains Protalix BioTherapeutics (PLX) Buy Recommendation | https://www.nasdaq.com/articles/hc-wainwright-co-maintains-protalix-biotherapeutics-plx-buy-recommendation
  • N5 | 2025-08-14 | www.nasdaq.com | Protalix Revenue Jumps 16 Percent in Q2 | https://www.nasdaq.com/articles/protalix-revenue-jumps-16-percent-q2
  • N6 | 2025-07-21 | www.nasdaq.com | Protalix BioTherapeutics Names Gilad Mamlok CFO | https://www.nasdaq.com/articles/protalix-biotherapeutics-names-gilad-mamlok-cfo
  • N7 | 2025-05-20 | www.nasdaq.com | Protalix BioTherapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 4:30 PM ET | https://www.nasdaq.com/articles/protalix-biotherapeutics-present-hc-wainwright-bioconnect-conference-webcast-4-30-pm-et
  • N8 | 2025-05-09 | www.nasdaq.com | $PLX Earnings Results: $PLX Reports Quarterly Earnings | https://www.nasdaq.com/articles/plx-earnings-results-plx-reports-quarterly-earnings
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine